Is NCT04219254 recruiting in San Antonio, TX?

Yes, NCT04219254 is currently recruiting participants at its San Antonio, TX location. This advanced solid tumors clinical trial is actively enrolling qualified participants.

How do I join the advanced solid tumors clinical trial in San Antonio?

To join this clinical trial in San Antonio, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this San Antonio clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Solid Tumors Clinical Trial in San Antonio, TX

Who Can Participate

Inclusion Criteria

Is willing and able to provide written informed consent for the trial.

Is ≥18 years of age on day of signing informed consent.

Phase I only: Has a histologically confirmed advanced solid tumor. Subjects must have received at least 2 doses of an approved anti-PD-1/L1 mAb, and have documented progression on or within 12 weeks from the last dose of anti-PD-1/L1 mAb.

For patients with NSCLC (phase 2A SC cohorts): Have a histologically confirmed diagnosis of advanced or metastatic NSCLC and not have an EGFR sensitizing (activating) mutation or an ALK translocation. Have a PD-L1 positive (TPS≥50%) tumor as determined by IHC at a local laboratory. Have not received prior systemic immunotherapy or chemotherapy treatment for their advanced/metastatic NSCLC. Have provided formalin-fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of advanced or metastatic disease has been made and from a lesion not previously irradiated to perform biomarker analysis. • For patients with uveal melanoma (phase 2A SC cohort): Have a histologically confirmed diagnosis of advanced or metastatic uveal melanoma Have a PD-L1 positive (TPS≥1%) tumor as determined by IHC at a local laboratory. Have not received prior systemic immunotherapy or chemotherapy treatment for their advanced/metastatic uveal melanoma. Subjects who have received previous treatment with tebentafusp and/or liver directed therapy are allowed. Have provided formalin-fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of advanced or metastatic disease has been made and from a site not previously irradiated to perform biomarker analysis.

Phase I only: Is intolerant of, refuses, or is not eligible for standard antineoplastic therapy.

Has at least 1 measurable disease lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

Phase IIa only: Is willing to provide an archival tumor tissue sample or newly obtained \[core, incisional, OR excisional\] biopsy of a tumor lesion not previously irradiated.

Is able to safely undergo a baseline tumor tissue biopsy prior to first dose of BI-1206.

Has a life expectancy of ≥12 weeks.

Has an ECOG performance status of 0-1.

Has adequate organ function as confirmed by laboratory values listed in the main body of the protocol

Phase IIa only: Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrolment

Phase IIa only: Participants with history of HCV infection are eligible if HCV viral load is undetectable at Screening

Phase IIa only: Has adequate hematological and biochemical indices as listed in the main body of the protocol

Exclusion Criteria

Needs doses of prednisolone \>10 mg daily (or equipotent doses of other corticosteroids) while on the study, other than as premedication.

Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Has known or suspected hypersensitivity to pembrolizumab or BI-1206 or any of their excipients.

Has cardiac or renal amyloid light-chain (AL) amyloidosis.

Has received radiotherapy within 2 weeks of the first dose of BI-1206.

Has not recovered from AEs to at least Grade 1 by CTCAE v5.0 (or higher) due to prior anticancer therapies• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis

Has an active, known or suspected autoimmune disease.

Is a female subject and has the ability to become pregnant (or already pregnant or lactating/breastfeeding)

Is a male subject with partner(s) of childbearing potential (unless he agrees to use a barrier method of contraception during the study and for 12 months after completing treatment)

Has had major surgery from which the subject has not yet recovered Is at high medical risk because of non-malignant systemic disease, including severe active infections on treatment with antibiotics, antifungals, or antivirals

Has presence of chronic graft-versus-host disease.

Has had an allogenic tissue/solid organ transplant.

Has a known history of HIV infection

Has a history of active tuberculosis (Bacillus tuberculosis)

Has received a live vaccine within 30 days before the first dose of study treatment

Has uncontrolled or significant cardiovascular disease as listed in the main body of the protocol

Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study

Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or lead to participation not being in the best interest of the subject, in the opinion of the treating Investigator.

Is participating or planning to participate in another interventional clinical study or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study drug

Has a known additional malignancy of another type, with the exception of adequately treated cone-biopsied carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) and basal or squamous cell carcinoma of the skin

Has a diagnosis of primary or acquired immunodeficiency disorder or has taken any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.

Is unable to attend the study site to receive the study treatment Additional exclusion criteria are described in the protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Antonio?

Yes, this clinical trial (NCT04219254) has an active research site in San Antonio, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in San Antonio, TX

If you're searching for advanced solid tumors treatment options in San Antonio, TX, this clinical trial (NCT04219254) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Antonio research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

Advanced Solid Tumors Clinical Trial in San Antonio, TX

Expert Care in San Antonio

IRB Approved

No-Cost Care

Apply for This San Antonio Location

Why Participate?

Simple Process

About This Advanced Solid Tumors Study in San Antonio